Compare iShares MSCI China ETF (MCHI) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Stryker Corporation — how do they compare? iShares MSCI China ETF trades at $52.48 (market cap $5.94B), while Stryker Corporation trades at $278.88 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 17.9× iShares MSCI China ETF's market cap, and Stryker Corporation pays a 1.27% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Stryker Corporation for 20 Days on average.
| MCHI | SYK | |
|---|---|---|
Market Cap | $5.94B | $106.24B |
Volume | 1,575,471 | 2,982,001 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $388.35 |
52-Week Low | $50.48 | $269.75 |
Typical Hold Time | 63 Days | 20 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI, the iShares MSCI China ETF, trades at $51.64, down 1.11% with a bearish technical outlook. The ETF faces pressure from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights mixed signals with strong corporate profit growth but concerns about export controls and trade tensions. Technical indicators show strong bearish momentum with moving averages signaling sell pressure while oscillators remain neutral.
The outlook remains cautious given China's macroeconomic headwinds and trade uncertainties. Investment opportunity exists in MCHI's significant discount to historical valuations compared to US indices, but risks include potential export restrictions, protectionism threats, and ongoing economic rebalancing challenges that could pressure Chinese equities.
Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.
Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
